Bujie Du
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bujie Du has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
Mingze Xu
The Second Affiliated Hospital of South China University of Technology (Guangzhou First People’s Hospital)
12 shared publications- Xingya Jiang
South China University of Technology Guangzhou International Campus
12 shared publications Yexi Peng
The Second Affiliated Hospital of South China University of Technology (Guangzhou First People’s Hospital)
11 shared publicationsYuming Qi
The Second Affiliated Hospital of South China University of Technology (Guangzhou First People’s Hospital)
11 shared publicationsHuixu Lu
South China University of Technology Guangzhou International Campus
10 shared publicationsXiaoxian Wang
The Second Affiliated Hospital of South China University of Technology (Guangzhou First People’s Hospital)
8 shared publications
Latest Publications
- 10 August 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (32) , 22517-22529
Boosting Cellular Glutathione Accelerates Elimination of Engineered Ultrasmall Nanoparticles from Kidneys and Liver by Promoting Exosome Release
Being two major detoxifying organs for in vivo clearance of nanoparticles, the kidneys and liver are susceptible to prolonged accumulation of engineered nanoparticles and associated side effects, particularly for the nondegradable ones. Thus, strategies that expedite the elimination of accumulated nanoparticles from these organs are in high demand. Herein, using two engineered ultrasmall gold nanoparticles that respectively accumulate in the kidneys and liver as models, we showed that orally supplementing N-acetylcysteine (NAC), a clinical drug and precursor of glutathione (GSH), significantly accelerated the elimination of accumulated ultrasmall gold nanoparticles in the kidneys and liver while promoting their renal and hepatobiliary excretion in mice. This enhanced elimination effect stemmed from NAC-induced elevation of intracellular GSH levels, which facilitates endocytosed ultrasmall nanoparticles to be exocytosed via exosomes instead of prolonged trapping in the lysosomes, a mechanism distinct from the conventional transporter-mediated export of small-molecule xenobiotics through GSH conjugation. Moreover, this promotion of exosome release was found to be independent of nanoparticle treatment but a natural cellular response to boosted GSH levels by NAC. Our findings thus demonstrate NAC supplementation as a potential strategy for accelerating the excretion of ultrasmall nanoparticles from the kidneys and liver, offering insights into the role of GSH in facilitating cellular elimination of substances.
- 10 August 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (32) , 22517-22529
Boosting Cellular Glutathione Accelerates Elimination of Engineered Ultrasmall Nanoparticles from Kidneys and Liver by Promoting Exosome Release
Being two major detoxifying organs for in vivo clearance of nanoparticles, the kidneys and liver are susceptible to prolonged accumulation of engineered nanoparticles and associated side effects, particularly for the nondegradable ones. Thus, strategies that expedite the elimination of accumulated nanoparticles from these organs are in high demand. Herein, using two engineered ultrasmall gold nanoparticles that respectively accumulate in the kidneys and liver as models, we showed that orally supplementing N-acetylcysteine (NAC), a clinical drug and precursor of glutathione (GSH), significantly accelerated the elimination of accumulated ultrasmall gold nanoparticles in the kidneys and liver while promoting their renal and hepatobiliary excretion in mice. This enhanced elimination effect stemmed from NAC-induced elevation of intracellular GSH levels, which facilitates endocytosed ultrasmall nanoparticles to be exocytosed via exosomes instead of prolonged trapping in the lysosomes, a mechanism distinct from the conventional transporter-mediated export of small-molecule xenobiotics through GSH conjugation. Moreover, this promotion of exosome release was found to be independent of nanoparticle treatment but a natural cellular response to boosted GSH levels by NAC. Our findings thus demonstrate NAC supplementation as a potential strategy for accelerating the excretion of ultrasmall nanoparticles from the kidneys and liver, offering insights into the role of GSH in facilitating cellular elimination of substances.
- 30 July 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (31) , 21812-21826
Size Effect of Nanoparticles on Targeting Injured Kidneys for Enhanced Intervention in Acute Kidney Injury
Nanoparticles show great potential for the management of acute kidney injuries (AKIs). It is well known that nanoparticle size plays a critical role in targeting renal tubules due to the pore structure and kidney filtration threshold (KFT) of the glomerulus. However, AKI can compromise the physiological barriers, which might render the established KFT (∼6 nm) and size laws under healthy conditions not applicable in AKI conditions. Reinvestigating the nanoparticle size effect on targeting injured kidneys is thus essential for developing efficacious AKI nanomedicine. Herein, using different-sized gold nanoparticles (AuNPs) ranging from 4 to 60 nm as a model of renal nanomedicine, we discovered that the KFT for AuNPs expands from ∼6 nm to ∼10–40 nm under rhabdomyolysis-induced AKI conditions. After loading curcumin, a natural antioxidant, into 5, 16, and 60 nm AuNPs to compare their efficacies against AKI, we found that 5 and 16 nm AuNPs both effectively delivered drugs into renal tubules, resulting in their equal therapeutic performance and significantly better efficacy than 60 nm ones, further validating the enlarged KFT under AKI. Our results provide valuable insights for size engineering of nanomedicine for better AKI management and enable a deeper understanding of AKI renal physiology at the nanoscale.
- 30 July 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (31) , 21812-21826
Size Effect of Nanoparticles on Targeting Injured Kidneys for Enhanced Intervention in Acute Kidney Injury
Nanoparticles show great potential for the management of acute kidney injuries (AKIs). It is well known that nanoparticle size plays a critical role in targeting renal tubules due to the pore structure and kidney filtration threshold (KFT) of the glomerulus. However, AKI can compromise the physiological barriers, which might render the established KFT (∼6 nm) and size laws under healthy conditions not applicable in AKI conditions. Reinvestigating the nanoparticle size effect on targeting injured kidneys is thus essential for developing efficacious AKI nanomedicine. Herein, using different-sized gold nanoparticles (AuNPs) ranging from 4 to 60 nm as a model of renal nanomedicine, we discovered that the KFT for AuNPs expands from ∼6 nm to ∼10–40 nm under rhabdomyolysis-induced AKI conditions. After loading curcumin, a natural antioxidant, into 5, 16, and 60 nm AuNPs to compare their efficacies against AKI, we found that 5 and 16 nm AuNPs both effectively delivered drugs into renal tubules, resulting in their equal therapeutic performance and significantly better efficacy than 60 nm ones, further validating the enlarged KFT under AKI. Our results provide valuable insights for size engineering of nanomedicine for better AKI management and enable a deeper understanding of AKI renal physiology at the nanoscale.
- 23 April 2026
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 26 (17) , 5925-5933
Rapid Tubular Accumulation of Renal-Clearable Gold Nanoparticles Enhances Computed Tomography Contrast Imaging of the Kidneys
Renal-clearable gold nanoparticles (RC-AuNPs) show promise for kidney computed tomography (CT) imaging by providing structural and functional information. To aid their clinical translation, understanding how their physicochemical properties affect renal CT enhancement is essential. By a head-to-head comparison of glutathione-coated and PEGylated RC-AuNPs (GS-AuNPs and PEG-AuNPs, respectively), we found that while PEG-AuNPs were renally cleared, their slower tubular entry at the early phase led to their suboptimal renal enhancement. Moreover, although surface folate modification enhanced RC-AuNP renal accumulation via actively targeting folate receptors on the tubular epithelium, their slower transport into tubules weakened renal enhancement. The effective renal CT enhancement by RC-AuNPs was not determined by their overall renal accumulation efficiency, but by their rapid entry into tubules, which can be reflected by their kidney:blood ratio 10 min after administration. Our work highlighted the superior performance of zwitterionic RC-AuNPs and provided design guidelines for developing better renal CT contrast agents.
- 23 April 2026
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 26 (17) , 5925-5933
Rapid Tubular Accumulation of Renal-Clearable Gold Nanoparticles Enhances Computed Tomography Contrast Imaging of the Kidneys
Renal-clearable gold nanoparticles (RC-AuNPs) show promise for kidney computed tomography (CT) imaging by providing structural and functional information. To aid their clinical translation, understanding how their physicochemical properties affect renal CT enhancement is essential. By a head-to-head comparison of glutathione-coated and PEGylated RC-AuNPs (GS-AuNPs and PEG-AuNPs, respectively), we found that while PEG-AuNPs were renally cleared, their slower tubular entry at the early phase led to their suboptimal renal enhancement. Moreover, although surface folate modification enhanced RC-AuNP renal accumulation via actively targeting folate receptors on the tubular epithelium, their slower transport into tubules weakened renal enhancement. The effective renal CT enhancement by RC-AuNPs was not determined by their overall renal accumulation efficiency, but by their rapid entry into tubules, which can be reflected by their kidney:blood ratio 10 min after administration. Our work highlighted the superior performance of zwitterionic RC-AuNPs and provided design guidelines for developing better renal CT contrast agents.
- 14 March 2026
- Published by Wiley in Chemistry – A European Journal
- Vol. 32 (21) , e03652
Tuning in Vivo Transport of Organic Dyes by Renal‐Clearable Gold Nanoparticles for Prolonged Kidney Imaging and Reporting Unilateral Kidney Injuries
The detection of unilateral kidney injury remains challenging owing to the intrinsic compensatory mechanism of the kidneys. Noninvasive kidney imaging using renal‐clearable near‐infrared (NIR) agents has shown promise in evaluating renal function. To enable accurate detection of unilateral kidney injury, herein, we developed a high‐contrast NIR imaging agent of 800CW‐Au by conjugating IRDye800CW with renal‐clearable gold nanoparticles (Au 25 SG 18 ). Compared with free IRDye800CW, the pharmacokinetics of the dye was significantly tailored after conjugation on Au 25 SG 18 , resulting in enhanced blood retention, reduced vascular extravasation, and lower affinity with background tissue. Consequently, 800CW‐Au achieved noninvasive kidney imaging with contrast enhancement > 100% for up to 12 h, much longer than the previously reported zwitterionic ZW800‐1 (∼10 min) and PEGylated IRDye800CW (∼4 min). We then established two representative mouse models of unilateral kidney injuries, including unilateral ureteral obstruction and ischemia‐reperfusion injury. According to its kinetics of renal enhancement and derived parameters, 800CW‐Au sensitively detected the functional impairment in the injured kidney and the compensatory hyperfiltration in the contralateral kidney, which the conventional blood biomarkers and global glomerular filtration rate were all insensitive to detect. This strategy of our work will provide guidance for developing renal NIR agents and advance the noninvasive detection of unilateral kidney injury.
- 14 March 2026
- Published by Wiley in Chemistry – A European Journal
- Vol. 32 (21) , e03652
Tuning in Vivo Transport of Organic Dyes by Renal‐Clearable Gold Nanoparticles for Prolonged Kidney Imaging and Reporting Unilateral Kidney Injuries
The detection of unilateral kidney injury remains challenging owing to the intrinsic compensatory mechanism of the kidneys. Noninvasive kidney imaging using renal‐clearable near‐infrared (NIR) agents has shown promise in evaluating renal function. To enable accurate detection of unilateral kidney injury, herein, we developed a high‐contrast NIR imaging agent of 800CW‐Au by conjugating IRDye800CW with renal‐clearable gold nanoparticles (Au 25 SG 18 ). Compared with free IRDye800CW, the pharmacokinetics of the dye was significantly tailored after conjugation on Au 25 SG 18 , resulting in enhanced blood retention, reduced vascular extravasation, and lower affinity with background tissue. Consequently, 800CW‐Au achieved noninvasive kidney imaging with contrast enhancement > 100% for up to 12 h, much longer than the previously reported zwitterionic ZW800‐1 (∼10 min) and PEGylated IRDye800CW (∼4 min). We then established two representative mouse models of unilateral kidney injuries, including unilateral ureteral obstruction and ischemia‐reperfusion injury. According to its kinetics of renal enhancement and derived parameters, 800CW‐Au sensitively detected the functional impairment in the injured kidney and the compensatory hyperfiltration in the contralateral kidney, which the conventional blood biomarkers and global glomerular filtration rate were all insensitive to detect. This strategy of our work will provide guidance for developing renal NIR agents and advance the noninvasive detection of unilateral kidney injury.
- Top Cited Papers
- 21 February 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (9) , 7805-7816
Priming the Liver Endocytic Pathway to Accelerate Hepatobiliary Clearance of Nanoparticles
Prolonged hepatic accumulation represents a major obstacle for clinical translation of many nanomedicines, particularly for those not easily biodegradable. While many strategies such as PEGylation have been developed to reduce or delay the liver uptake of nanoparticles, strategies that expedite nanoparticle elimination after liver uptake are rarely reported. Herein, we report a broadly applicable strategy to accelerate hepatobiliary elimination of diverse nanoparticles through priming of the liver endocytic pathway. Inspired by our findings that smaller gold nanoparticles exhibit inherently faster hepatobiliary clearance due to size-dependent endocytic pathways, we discovered that inhibition of clathrin-mediated endocytosis (CME) significantly enhances nanoparticle exocytosis from hepatocytes and macrophages. Mechanistically, we found that CME inhibition alters nanoparticle intracellular trafficking, diverting endocytosed nanoparticles from the lysosomal pathway to the Golgi apparatus for faster exocytosis. Using the clinically approved drug chlorpromazine as a CME inhibitor, we demonstrated that priming the liver with chlorpromazine markedly accelerated hepatobiliary clearance and reduced hepatic retention of various nanoparticles ranging from inorganic to organic ones in mice. Moreover, in a murine tumor model, we showed that hepatic CME inhibition accelerated hepatobiliary elimination of the model nanomedicine without compromising its disease targeting efficacy. Our discovery highlights a versatile strategy for accelerating hepatobiliary elimination of nanoparticles, which is expected to synergize with previous strategies for overcoming nonspecific liver accumulation of nanomedicines.
- 21 February 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (9) , 7805-7816
Top Cited PapersPriming the Liver Endocytic Pathway to Accelerate Hepatobiliary Clearance of Nanoparticles
Prolonged hepatic accumulation represents a major obstacle for clinical translation of many nanomedicines, particularly for those not easily biodegradable. While many strategies such as PEGylation have been developed to reduce or delay the liver uptake of nanoparticles, strategies that expedite nanoparticle elimination after liver uptake are rarely reported. Herein, we report a broadly applicable strategy to accelerate hepatobiliary elimination of diverse nanoparticles through priming of the liver endocytic pathway. Inspired by our findings that smaller gold nanoparticles exhibit inherently faster hepatobiliary clearance due to size-dependent endocytic pathways, we discovered that inhibition of clathrin-mediated endocytosis (CME) significantly enhances nanoparticle exocytosis from hepatocytes and macrophages. Mechanistically, we found that CME inhibition alters nanoparticle intracellular trafficking, diverting endocytosed nanoparticles from the lysosomal pathway to the Golgi apparatus for faster exocytosis. Using the clinically approved drug chlorpromazine as a CME inhibitor, we demonstrated that priming the liver with chlorpromazine markedly accelerated hepatobiliary clearance and reduced hepatic retention of various nanoparticles ranging from inorganic to organic ones in mice. Moreover, in a murine tumor model, we showed that hepatic CME inhibition accelerated hepatobiliary elimination of the model nanomedicine without compromising its disease targeting efficacy. Our discovery highlights a versatile strategy for accelerating hepatobiliary elimination of nanoparticles, which is expected to synergize with previous strategies for overcoming nonspecific liver accumulation of nanomedicines.
- 18 February 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (8) , 6875-6890
Precisely Staging Diabetic Nephropathy by a Gold-Based Artificial Filtration Biomarker through Computed Tomography and Blood Testing of the Glomerular Filtration Rate
Diabetic nephropathy (DN) has become a global health burden associated with high morbidity and mortality. Quantitative staging of DN is crucial for its timely and stage-matched therapeutic intervention. Given that glomerular dysfunction is the pathological hallmark of DN progression, the glomerular filtration rate (GFR) is the most comprehensive indicator of DN. However, estimated GFR derived from endogenous serum creatinine is inaccurate for precise staging of DN. To address this issue, we developed an exogenous gold-based artificial filtration biomarker (Gold-AFB), realizing accurate measurement of GFR alteration during DN progression through computed tomography (CT) imaging or simple blood testing. The Gold-AFB comprised an ultrasmall gold core and a strongly antifouling phosphatidylcholine shell, which enabled its rapid and free glomerular filtration (>90%@2 h, ∼100%@24 h) without tubular interactions. Leveraging the high X-ray attenuation properties of Gold-AFB, we achieved accurate quantification of GFR via rapid renal CT imaging and realized the differentiation of three DN stages, covering phases from glomerular hyperfiltration to mild and severe glomerulosclerosis, which were hardly distinguished by endogenous biomarkers. Furthermore, we also established a blood-based assay using Gold-AFB, realizing a convenient GFR report in murine and rabbit models at a 100-fold lower dose than FITC-inulin, the current "gold" standard for GFR measurement.
- 18 February 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (8) , 6875-6890
Precisely Staging Diabetic Nephropathy by a Gold-Based Artificial Filtration Biomarker through Computed Tomography and Blood Testing of the Glomerular Filtration Rate
Diabetic nephropathy (DN) has become a global health burden associated with high morbidity and mortality. Quantitative staging of DN is crucial for its timely and stage-matched therapeutic intervention. Given that glomerular dysfunction is the pathological hallmark of DN progression, the glomerular filtration rate (GFR) is the most comprehensive indicator of DN. However, estimated GFR derived from endogenous serum creatinine is inaccurate for precise staging of DN. To address this issue, we developed an exogenous gold-based artificial filtration biomarker (Gold-AFB), realizing accurate measurement of GFR alteration during DN progression through computed tomography (CT) imaging or simple blood testing. The Gold-AFB comprised an ultrasmall gold core and a strongly antifouling phosphatidylcholine shell, which enabled its rapid and free glomerular filtration (>90%@2 h, ∼100%@24 h) without tubular interactions. Leveraging the high X-ray attenuation properties of Gold-AFB, we achieved accurate quantification of GFR via rapid renal CT imaging and realized the differentiation of three DN stages, covering phases from glomerular hyperfiltration to mild and severe glomerulosclerosis, which were hardly distinguished by endogenous biomarkers. Furthermore, we also established a blood-based assay using Gold-AFB, realizing a convenient GFR report in murine and rabbit models at a 100-fold lower dose than FITC-inulin, the current "gold" standard for GFR measurement.
- 16 January 2026
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 26 (3) , 1135-1142
Alloying Impacts In Vivo Behaviors of Ultrasmall Noble-Metal Nanoparticles through Intermetallic Charge-Transfer Mediated Ligand-Core Interactions
Noble-metal nanoparticles (NMNPs) show great promise for their biomedical use. While it is known that surface ligands vastly impact their biological fate in vivo, the influence of ligand-core interactions remains underexplored. Herein, we showed that ultrasmall mercaptosuccinic acid (MSA)-coated gold/platinum (Au/Pt) alloy nanoparticles exhibited distinct in vivo targeting and clearance behaviors compared to their monometallic analogs, despite having identical surface ligands. Mechanistic studies revealed much stronger noncovalent ligand-core interactions in the alloy nanoparticles relative to the monometallic nanoparticles, due to intermetallic charge-transfer of the alloyed core. This enhanced ligand-core interaction further attenuated nanoparticle surface charge, leading to reduced serum protein adsorption and recognition by the mononuclear phagocyte system and eventually resulting in distinct in vivo behaviors. Our findings thus highlight the ligand-core interactions in regulating biological behaviors of NMNPs through affecting nanoparticle surface charge and protein adsorption, suggesting core composition as a tunable parameter for modulating the nano-bio interactions.
- 16 January 2026
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 26 (3) , 1135-1142
Alloying Impacts In Vivo Behaviors of Ultrasmall Noble-Metal Nanoparticles through Intermetallic Charge-Transfer Mediated Ligand-Core Interactions
Noble-metal nanoparticles (NMNPs) show great promise for their biomedical use. While it is known that surface ligands vastly impact their biological fate in vivo, the influence of ligand-core interactions remains underexplored. Herein, we showed that ultrasmall mercaptosuccinic acid (MSA)-coated gold/platinum (Au/Pt) alloy nanoparticles exhibited distinct in vivo targeting and clearance behaviors compared to their monometallic analogs, despite having identical surface ligands. Mechanistic studies revealed much stronger noncovalent ligand-core interactions in the alloy nanoparticles relative to the monometallic nanoparticles, due to intermetallic charge-transfer of the alloyed core. This enhanced ligand-core interaction further attenuated nanoparticle surface charge, leading to reduced serum protein adsorption and recognition by the mononuclear phagocyte system and eventually resulting in distinct in vivo behaviors. Our findings thus highlight the ligand-core interactions in regulating biological behaviors of NMNPs through affecting nanoparticle surface charge and protein adsorption, suggesting core composition as a tunable parameter for modulating the nano-bio interactions.
- Open Access
- 22 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-17
Reno-protective CT contrast nanoagent targets proximal tubular epithelium for kidney disease imaging and repair in a mouse model
| CT imaging is widely used in clinics for disease diagnosis, but its application in renal function evaluation is limited due to nonspecific distribution and nephrotoxicity of clinical iodinated contrast agents. Herein, we developed an ultrasmall renal-clearable gold nanoparticle-based CT contrast nanoagent (E-Au-Agents) coated with antioxidant L-ergothioneine, enabling reno-targeting and reno-protection for sensitive detection and effective relief of renal dysfunction in female mice. After glomerular filtration, E-Au-Agents specifically recognized OCTN1 transporters on proximal tubular epithelium, followed by clathrin-mediated endocytosis with subsequent tubular reabsorption or re-elimination pathways. This tubular-targeting was markedly enhanced in injured kidneys, allowing rapid CT detection of acute kidney injury, followed by oxidative stress suppression. Remarkably, E-Au-Agents progressively repaired injured kidneys, allowing their eventual clearance through recovered kidneys instead of long-term renal accumulation, a drawback commonly observed in other renal-clearable agents. Collectively, we developed a promising contrast agent for renal CT imaging with dual capabilities of reno-targeting and reno-protection.
- 22 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-17
Open AccessReno-protective CT contrast nanoagent targets proximal tubular epithelium for kidney disease imaging and repair in a mouse model
| CT imaging is widely used in clinics for disease diagnosis, but its application in renal function evaluation is limited due to nonspecific distribution and nephrotoxicity of clinical iodinated contrast agents. Herein, we developed an ultrasmall renal-clearable gold nanoparticle-based CT contrast nanoagent (E-Au-Agents) coated with antioxidant L-ergothioneine, enabling reno-targeting and reno-protection for sensitive detection and effective relief of renal dysfunction in female mice. After glomerular filtration, E-Au-Agents specifically recognized OCTN1 transporters on proximal tubular epithelium, followed by clathrin-mediated endocytosis with subsequent tubular reabsorption or re-elimination pathways. This tubular-targeting was markedly enhanced in injured kidneys, allowing rapid CT detection of acute kidney injury, followed by oxidative stress suppression. Remarkably, E-Au-Agents progressively repaired injured kidneys, allowing their eventual clearance through recovered kidneys instead of long-term renal accumulation, a drawback commonly observed in other renal-clearable agents. Collectively, we developed a promising contrast agent for renal CT imaging with dual capabilities of reno-targeting and reno-protection.
- 8 October 2025
- Published by American Chemical Society (ACS) in ACS Nano Medicine
- Vol. 1 (2) , 427-437
Quantitative Detection of Bilateral and Unilateral Renal Dysfunction by Gold Nanoparticles through CT Imaging
- 8 October 2025
- Published by American Chemical Society (ACS) in ACS Nano Medicine
- Vol. 1 (2) , 427-437
Quantitative Detection of Bilateral and Unilateral Renal Dysfunction by Gold Nanoparticles through CT Imaging
- 26 September 2025
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 19 (39) , 34772-34784
Charge-Pairing Enabled Renal-Clearable Chemiluminescent Gold Nanoprobes for Ratiometric Imaging and Urinalysis of Pathological Reactive Oxygen Species
Excessive generation of reactive oxygen species (ROS) is a hallmark of many diseases and represents an important molecular signal for early disease detection. Chemiluminescent probes hold potential for ROS detection, yet they are often hindered by high mononuclear phagocyte system (MPS) uptake, limited light penetration depth, and single-signal readout in vivo. Herein, we report renal-clearable ratiometric chemiluminescent ROS nanoprobes (ABEI-MSA-AuNPs) by simply conjugating cationic chemiluminescent molecules, N-(4-aminobutyl)-N-ethylisoluminol (ABEI), onto the surface of anionic ultrasmall mercaptosuccinic acid (MSA)-coated gold nanoparticles (MSA-AuNPs). Strikingly, although neither ABEI nor MSA-AuNPs are intrinsically renal clearable, conjugating ABEI onto MSA-AuNPs results in efficient renal clearance and reduces the level of hepatic sequestration of AuNPs by nearly 100-fold, which is due to a charge-pairing effect that effectively suppresses opsonization and MPS recognition. The large Stokes shift of luminescent MSA-AuNPs allows energy transfer from ABEI to MSA-AuNPs for ROS-triggered chemiluminescence emission beyond 800 nm. Leveraging ROS-sensitive chemiluminescence and ROS-insensitive photoluminescence signals, we show that ABEI-MSA-AuNPs permit noninvasive detection of pathological ROS through dual-channel ratiometric imaging and ratiometric urinalysis using multiple disease models. Our discoveries highlight a charge-pairing strategy for constructing chemiluminescent probes with ultralow MPS uptake, efficient renal elimination, and ratiometric readout, showing promise in early detection of ROS-associated pathological events in vivo.
- 26 September 2025
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 19 (39) , 34772-34784
Charge-Pairing Enabled Renal-Clearable Chemiluminescent Gold Nanoprobes for Ratiometric Imaging and Urinalysis of Pathological Reactive Oxygen Species
Excessive generation of reactive oxygen species (ROS) is a hallmark of many diseases and represents an important molecular signal for early disease detection. Chemiluminescent probes hold potential for ROS detection, yet they are often hindered by high mononuclear phagocyte system (MPS) uptake, limited light penetration depth, and single-signal readout in vivo. Herein, we report renal-clearable ratiometric chemiluminescent ROS nanoprobes (ABEI-MSA-AuNPs) by simply conjugating cationic chemiluminescent molecules, N-(4-aminobutyl)-N-ethylisoluminol (ABEI), onto the surface of anionic ultrasmall mercaptosuccinic acid (MSA)-coated gold nanoparticles (MSA-AuNPs). Strikingly, although neither ABEI nor MSA-AuNPs are intrinsically renal clearable, conjugating ABEI onto MSA-AuNPs results in efficient renal clearance and reduces the level of hepatic sequestration of AuNPs by nearly 100-fold, which is due to a charge-pairing effect that effectively suppresses opsonization and MPS recognition. The large Stokes shift of luminescent MSA-AuNPs allows energy transfer from ABEI to MSA-AuNPs for ROS-triggered chemiluminescence emission beyond 800 nm. Leveraging ROS-sensitive chemiluminescence and ROS-insensitive photoluminescence signals, we show that ABEI-MSA-AuNPs permit noninvasive detection of pathological ROS through dual-channel ratiometric imaging and ratiometric urinalysis using multiple disease models. Our discoveries highlight a charge-pairing strategy for constructing chemiluminescent probes with ultralow MPS uptake, efficient renal elimination, and ratiometric readout, showing promise in early detection of ROS-associated pathological events in vivo.